TESARO Inc (TSRO) Holdings Lifted by Peregrine Capital Management LLC
Peregrine Capital Management LLC boosted its stake in shares of TESARO Inc (NASDAQ:TSRO) by 21.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 142,833 shares of the biopharmaceutical company’s stock after purchasing an additional 24,743 shares during the quarter. Peregrine Capital Management LLC’s holdings in TESARO were worth $11,837,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Exane Derivatives acquired a new position in TESARO during the third quarter worth about $106,000. Nordea Investment Management AB acquired a new position in TESARO during the second quarter worth about $167,000. Toronto Dominion Bank grew its position in TESARO by 244.6% during the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,130 shares during the period. Achmea Investment Management B.V. acquired a new position in TESARO during the second quarter worth about $234,000. Finally, Commonwealth Equity Services Inc acquired a new position in TESARO during the third quarter worth about $222,000.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 40.50% of the stock is currently owned by company insiders.
Shares of TESARO Inc (TSRO) opened at $71.02 on Friday. TESARO Inc has a 1 year low of $59.77 and a 1 year high of $192.94. The stock has a market cap of $3,860.00, a P/E ratio of -8.42 and a beta of 1.51. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73.
TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. During the same quarter last year, the business earned ($1.72) earnings per share. TESARO’s revenue was up 740.3% compared to the same quarter last year. analysts forecast that TESARO Inc will post -8.19 EPS for the current year.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.